What is Mononeuritis Multiplex?
Mononeuritis multiplex is a severe peripheral nervous system disorder characterized by simultaneous or sequential damage to multiple, non-contiguous peripheral nerve trunks, typically presenting as asymmetric sensory and/or motor deficits in different nerve distributions. 1, 2
Clinical Presentation
The condition manifests with:
- Asymmetric nerve involvement: Multiple peripheral nerves affected in a non-continuous pattern, distinguishing it from symmetric polyneuropathy
- Sensory symptoms: Numbness, paresthesias, burning sensations, and sensory loss in specific nerve distributions 3
- Motor deficits: Muscle weakness or atrophy in affected nerve territories, which can be severe 1
- Pattern of onset: Symptoms may appear abruptly or develop subacutely, often affecting one nerve territory followed by others over time 3
Disease Associations and Pathophysiology
Mononeuritis multiplex is most commonly associated with:
- Vasculitis: The primary mechanism in systemic vasculitides including polyarteritis nodosa (PAN), ANCA-associated vasculitis (AAV), and eosinophilic granulomatosis with polyangiitis (EGPA) 1, 4, 2
- Immune-mediated injury: Direct autoantibody-mediated nerve damage or ischemic injury from immune complex deposition 3
- Systemic diseases: Hepatitis C-related cryoglobulinemia, systemic lupus erythematosus, diabetes, and infections 3, 5
The underlying pathophysiology typically involves ischemic nerve damage from vasculitic or vasculopathic processes affecting the vasa nervorum (blood vessels supplying peripheral nerves) 3.
Clinical Significance in Vasculitis
In the context of systemic vasculitis, mononeuritis multiplex is classified as a severe, organ-threatening manifestation requiring aggressive immunosuppressive therapy. 1
According to the 2021 ACR/Vasculitis Foundation guidelines for PAN, mononeuritis multiplex is explicitly defined as a severe disease manifestation warranting:
- Immediate treatment with cyclophosphamide and high-dose glucocorticoids 1
- Combined nerve and muscle biopsy (preferred over nerve biopsy alone) for diagnostic confirmation 1
In EGPA, mononeuritis multiplex occurs in 50-70% of patients and represents a vasculitic manifestation that may influence treatment decisions, particularly regarding the use of rituximab in ANCA-positive patients 4, 2, 6.
Diagnostic Approach
Essential diagnostic steps include:
Electrophysiological studies: Nerve conduction studies and electromyography to confirm multifocal axonal neuropathy pattern and distinguish from polyneuropathy 5, 7
Tissue biopsy: Combined nerve and muscle biopsy showing necrotizing vasculitis, perivascular inflammation, or axonal degeneration provides definitive diagnosis 1
Laboratory evaluation: ANCA testing, cryoglobulins, hepatitis serology, and autoimmune markers to identify underlying systemic disease 3
Imaging: When vasculitis is suspected, vascular imaging may identify associated organ involvement 1
Critical Clinical Pitfall
Do not confuse mononeuritis multiplex with symmetric polyneuropathy. The asymmetric, multifocal pattern is the defining feature. Serial neurologic examinations are recommended for monitoring rather than repeated electrophysiological studies 1. The presence of mononeuritis multiplex should prompt urgent evaluation for systemic vasculitis or other life-threatening conditions, as delayed treatment can result in permanent neurological disability 1, 2.